Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: CALGB C80802 - PHASE III RANDOMIZED STUDY OF SORAFENIB PLUS DOXORUBICIN VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

 


CALGB C80802 - PHASE III RANDOMIZED STUDY OF SORAFENIB PLUS DOXORUBICIN VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)


Trial Focus

Digestive System Cancer

Objective

         This is a clinical trial of sorafenib that will be administered by mouth, which is investigational and doxorubicin that will be administered by IV and is standard of care.

IRB Protocol #

12-0123

Trial Status

Archived

Principle Investigator

WELLS MESSERSMITH

Sponsor

CALGB

Contact

DAVID SHENEMAN at (720)848-0286 or DAVID.SHENEMAN@UCDENVER.EDU

Location

ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Valley View Hospital ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Valley View Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period(s) that can last up to 3 years. A follow up period will consist of clinic visit // Eligibility criteria include but are not limited to 18 years or older with advanced primary liver cancer.Eligibility criteria include but are not limited to 18 years or older with advanced primary liver cancer.